Ascendis Pharma A/S (ASND)

Market Cap	12.55B
Revenue (ttm)	758.59M
Net Income (ttm)	-273.31M
Shares Out	61.10M
EPS (ttm)	-4.54
PE Ratio	n/a
Forward PE	97.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	470,721
Open	209.46
Previous Close	208.58
Day's Range	204.94 - 212.00
52-Week Range	118.03 - 223.19
Beta	0.44
Analysts	Strong Buy
Price Target	256.27 (+24.74%)
Earnings Date	Nov 12, 2025

About ASND

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 28, 2015
• Employees: 1,017
• Stock Exchange: NASDAQ
• Ticker Symbol: ASND
• Website: https://ascendispharma.com

Financial Performance

In 2024, Ascendis Pharma's revenue was 363.64 million, an increase of 36.34% compared to the previous year's 266.72 million. Losses were -378.08 million, -21.47% less than in 2023.

Financial numbers in EUR

Analyst Forecast

According to 15 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price target is $256.27, which is an increase of 24.74% from the latest price.

Price Target

$256.27

(24.74% upside)

Analyst Consensus: Strong Buy